Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab

Introduction Immune checkpoint inhibitors (CPIs) have changed the treatment landscape for many cancers, but also cause severe inflammatory side effects including enterocolitis. CPI-induced enterocolitis is treated empirically with corticosteroids, and infliximab (IFX) is used in corticosteroid-refra...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Hajir Ibraheim, Sophie Papa, Nick Powell, James L Alexander, James Larkin, Samra Turajlic, Andrew Furness, Julian P Teare, Paul Nathan, Dharmisha Chauhan, David J Pinato, Jessica Little, Raguprakash Ratnakumaran, Bhavisha Sheth, Muhammad Saheb Khan, Camellia Richards, Nikki Hunter, Kathleen McHugh, Julia Choy, Shanthini M Crusz, Lisa Pickering, Ally Speight, Anand Sharma
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMJ Publishing Group 2021-07-01
Serier:	Journal for ImmunoTherapy of Cancer
Online adgang:	https://jitc.bmj.com/content/9/7/e002742.full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!